By PathAILearning Objectives
- Understand what digital pathology AI is and how it improves diagnosis
- Evaluate PathAI's FDA-cleared products and national lab partnerships
- Assess PathAI's role in both clinical diagnosis and pharmaceutical clinical trials
What Is PathAI?
PathAI builds AI tools for pathology — the medical specialty that diagnoses diseases by examining tissue samples under microscopes. PathAI's platform digitizes these glass slides and applies AI to detect tumors, grade cancers, and identify disease patterns faster and more consistently than human review alone.
Key products include AISight Dx (FDA-cleared for primary diagnosis), AIM-MASH (first AI pathology tool FDA-qualified for clinical trials), and PathAssist Derm (FDA Breakthrough Device Designation for dermatopathology).
In May 2026 Roche agreed to acquire PathAI for 750 million dollars upfront plus up to 300 million dollars in milestone payments. PathAI is to become part of Roche's Diagnostics division, which already sells the navify digital pathology platform, and Roche named the AISight image management software as a key asset. The deal was expected to close in the second half of 2026, subject to antitrust and regulatory approvals, and neither company had announced completion by mid-September 2026.
Key Products
| Product | FDA Status | What It Does |
|---|---|---|
| AISight Dx | FDA 510(k) cleared + CE marked | Digital pathology platform for primary diagnosis; deployed at Labcorp and Quest |
| AIM-MASH AI Assist | FDA Drug Development Tool qualified | First AI pathology tool qualified for MASH clinical trials |
| PathAssist Derm | FDA Breakthrough Device Designation | AI-powered dermatopathology workflow |
| AISight Image Management | Enterprise platform | Slide management and lab workflow across tumor types |
Company Details
| Detail | Info |
|---|---|
| Founded | 2016 |
| CEO | Andrew Beck, M.D., Ph.D. (co-founder) |
| Headquarters | Boston, Massachusetts |
| Employees | ~269 |
| Total Raised | ~$490 million |
| Key Investors | General Atlantic; Kaiser Permanente; Bristol-Myers Squibb |
| Key Partners | Labcorp (nationwide deployment); Quest Diagnostics ($100 million lab acquisition + license) |
| Pending Acquisition | Roche agreed to acquire PathAI in May 2026 ($750 million upfront, up to $300 million in milestones) |
| Website | pathai.com |
Key Takeaways
- PathAI is the leading AI digital pathology company with FDA-cleared tools for primary diagnosis and clinical trials
- Deployed nationally at Labcorp and Quest Diagnostics — the two largest US reference lab networks
- Only company with both an FDA-cleared primary diagnosis platform (AISight Dx) and an FDA-qualified clinical trial biomarker tool (AIM-MASH)
- Roche agreed in May 2026 to acquire PathAI for 750 million dollars upfront plus up to 300 million dollars in milestones, folding it into Roche Diagnostics once the deal closes
